Document:

Exhibit 10.5

 

UNIT SUBSCRIPTION AGREEMENT

 

This UNIT SUBSCRIPTION
AGREEMENT (this “Agreement”) is made as of the 12th day of December 2019, by and between Healthcare
Merger Corp., a Delaware corporation (the “Company”), having its principal place of business at 623 Fifth Avenue,
14th Floor, New York, NY 10022, and HCMC Sponsor LLC, a Delaware limited liability company (the “Subscriber”),
having its principal place of business at 623 Fifth Avenue, 14th Floor, New York, NY 10022.

 

WHEREAS, the Company
desires to sell to the Subscriber on a private placement basis (the “Offering”) an aggregate of 640,000 units
(or up to 706,000 units if the over-allotment option in connection with the IPO (as defined below) is exercised in full) (the “Units”)
of the Company, each Unit comprised of one share of Class A common stock of the Company, par value $0.0001 per share (“Common
Stock”) and one half of one warrant, each whole warrant exercisable to purchase one share of Common Stock (“Warrant”),
for a purchase price of $10.00 per Unit. The shares of Common Stock underlying the Warrants are hereinafter referred to as the
“Warrant Shares”. The shares of Common Stock underlying the Units (excluding the Warrant Shares) are hereinafter
referred to as the “Placement Shares.” The Warrants underlying the Units are hereinafter referred to as the
“Placement Warrants.” The Units, Placement Shares, Placement Warrants and Warrant Shares, collectively, are
hereinafter referred to as the “Securities.” Each whole Placement Warrant is exercisable to purchase one share
of Common Stock at an exercise price of $11.50 during the period commencing on the later of (i) twelve (12) months from the date
of the closing of the Company’s initial public offering of units (the “IPO”) and (ii) 30 days following
the consummation of the Company’s initial business combination (the “Business Combination”), as such term
is defined in the registration statement in connection with the IPO, as amended at the time it becomes effective (the “Registration
Statement”), and expiring on the fifth anniversary of the consummation of the Business Combination; and

 

WHEREAS, the Subscriber
wishes to purchase 640,000 Units (or up to 706,000 Units if the over-allotment option in connection with the IPO is exercised in
full), and the Company wishes to accept such subscription from Subscriber.

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants hereinafter set forth and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and Subscriber hereby agree as follows:

 

1. Agreement to Subscribe

 

1.1. Purchase and Issuance
of the Units. Upon the terms and subject to the conditions of this Agreement, the Subscriber hereby agrees to purchase from the
Company, and the Company hereby agrees to sell to the Subscriber, on the Initial Closing Date (as defined below) 640,000 Units
in consideration of the payment of the Purchase Price (as defined below). On the Initial Closing Date, the Company shall, at its
option, deliver to the Subscriber the certificates representing the Securities purchased or effect such delivery in book-entry
form.

 

1.2. Purchase Price.
The Subscriber shall pay $6,400,000 (the “Purchase Price”) by wire transfer of immediately available funds or
by such other method as may be reasonably acceptable to the Company, to the trust account (the “Trust Account”)
at a financial institution to be chosen by the Company, maintained by Continental Stock Transfer & Trust Company, acting as
trustee (“Continental”), one (1) business day prior to the date of effectiveness of the Registration Statement.

 

1.3. Initial Closing.
The closing of the purchase and sale of 640,000 Units shall take place simultaneously with the closing of the IPO (the “Initial
Closing Date”). The closing of such Units shall take place at the offices of Ellenoff Grossman & Schole LLP, 1345
Avenue of the Americas, 11th Floor, New York, New York, 10105, or such other place as may be agreed upon by the
parties hereto.

 

1.4. Purchase and Issuance
of Additional Units. Upon the terms and subject to the conditions of this Agreement, the Subscriber hereby agrees to purchase from
the Company, and the Company hereby agrees to sell to the Subscriber, on the Over-allotment Closing Date (as defined below) up
to an aggregate of 66,000 Units in consideration of the payments of the Over-allotment Purchase Price (as defined below) and in
the same proportion as the amount of the over-allotment option is exercised. On the Over-allotment Closing Date (as defined below),
the Company shall, at its option, deliver to the Subscriber the certificates representing the Securities purchased or effect such
delivery in book-entry form.

 

     

     

    

 

1.5. Purchase Price.
The Subscriber shall pay up to $660,000 (if the over-allotment option in connection with the IPO is exercised in full) (the “Over-allotment
Purchase Price”) by wire transfer of immediately available funds or by such other method as may be reasonably acceptable
to the Company, to the Trust Account on the date of the consummation of the closing of the over-allotment option, and concurrently
with the consummation thereof, or on such earlier time and date as may be mutually agreed by the Company and the Subscriber (each
such date, an “Over-allotment Closing Date”; together with the Initial Closing Date, the “Closing Dates”
and each, a “Closing Date”).

 

1.6. Over-Allotment
Closing. The Over-allotment Closing Date shall take place at the offices of Ellenoff Grossman & Schole LLP, 1345 Avenue of
the Americas, 11th Floor, New York, New York, 10105, or such other place as may be agreed upon by the parties hereto.

 

1.7 Termination. This
Agreement and each of the obligations of the undersigned shall be null and void and without effect if a Closing does not occur
prior to March 31, 2020.

 

2. Representations and Warranties
of Subscriber

 

Subscriber represents and warrants to the
Company that:

 

2.1. No Government
Recommendation or Approval. Subscriber understands that no federal or state agency has passed upon or made any recommendation or
endorsement of the Company or the Offering of the Securities.

 

2.2. Accredited Investor.
Subscriber represents that it is an “accredited investor” as such term is defined in Rule 501(a) of Regulation D under
the Securities Act of 1933, as amended (the “Securities Act”), and acknowledges that the sale contemplated hereby
is being made in reliance, among other things, on a private placement exemption to “accredited investors” under the
Securities Act and similar exemptions under state law.

 

2.3. Intent. Subscriber
is purchasing the Securities solely for investment purposes, for Subscriber’s own account (and/or for the account or benefit
of its members or affiliates, as permitted, pursuant to the terms of an agreement (the “Insider Letter”) to
be entered into with respect to the Securities between, among others, Subscriber and the Company, as described in the Registration
Statement), and not with a view to the distribution thereof and Subscriber has no present arrangement to sell the Securities to
or through any person or entity except as may be permitted under the Insider Letter. Subscriber shall not engage in hedging transactions
with regard to the Securities unless in compliance with the Securities Act.

 

2.4. Restrictions on
Transfer. Subscriber acknowledges and understands the Units are being offered in a transaction not involving a public offering
in the United States within the meaning of the Securities Act. The Securities have not been registered under the Securities Act
and, if in the future Subscriber decides to offer, resell, pledge or otherwise transfer the Securities, such Securities may be
offered, resold, pledged or otherwise transferred only (A) pursuant to an effective registration statement filed under the Securities
Act, (B) pursuant to an exemption from registration under Rule 144 promulgated under the Securities Act, if available, or (C) pursuant
to any other available exemption from the registration requirements of the Securities Act, and in each case in accordance with
any applicable securities laws of any state or any other jurisdiction. Notwithstanding the foregoing, Subscriber acknowledges and
understands the Securities are subject to transfer restrictions as described in Section 8 hereof. Subscriber agrees that if any
transfer of its Securities or any interest therein is proposed to be made, as a condition precedent to any such transfer, Subscriber
may be required to deliver to the Company an opinion of counsel satisfactory to the Company with respect to such transfer. Absent
registration or another available exemption from registration, Subscriber agrees it will not resell the Securities (unless otherwise
permitted pursuant to the Insider Letter, as described in the Registration Statement). Subscriber further acknowledges that because
the Company is a shell company, Rule 144 may not be available to Subscriber for the resale of the Securities until the one year
anniversary following consummation of the initial Business Combination of the Company, despite technical compliance with the requirements
of Rule 144 and the release or waiver of any contractual transfer restrictions.

 

    2

     

    

 

2.5. Sophisticated
Investor.

 

(i) Subscriber is
sophisticated in financial matters and is able to evaluate the risks and benefits of the investment in the Securities.

 

(ii) Subscriber is
aware that an investment in the Securities is highly speculative and subject to substantial risks because, among other things,
the Securities are subject to transfer restrictions and have not been registered under the Securities Act and therefore cannot
be sold unless subsequently registered under the Securities Act or an exemption from such registration is available. Subscriber
is able to bear the economic risk of its investment in the Securities for an indefinite period of time.

 

2.6. Independent Investigation.
Subscriber, in making the decision to purchase the Units, has relied upon an independent investigation of the Company and has not
relied upon any information or representations made by any third parties or upon any oral or written representations or assurances
from the Company, its officers, directors or employees or any other representatives or agents of the Company, other than as set
forth in this Agreement. Subscriber is familiar with the business, operations and financial condition of the Company and has had
an opportunity to ask questions of, and receive answers from the Company’s officers and directors concerning the Company
and the terms and conditions of the offering of the Units and has had full access to such other information concerning the Company
as Subscriber has requested. Subscriber confirms that all documents that it has requested have been made available and that Subscriber
has been supplied with all of the additional information concerning this investment which Subscriber has requested.

 

2.7 Organization and
Authority. Subscriber is duly organized, validly existing and in good standing under the laws of the State of Delaware and it possesses
all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.

 

2.8. Authority. This
Agreement has been validly authorized, executed and delivered by Subscriber and is a valid and binding agreement enforceable in
accordance with its terms, subject to the general principles of equity and to bankruptcy or other laws affecting the enforcement
of creditors’ rights generally.

 

2.9. No Conflicts.
The execution, delivery and performance of this Agreement and the consummation by Subscriber of the transactions contemplated hereby
do not violate, conflict with or constitute a default under (i) Subscriber's charter documents, (ii) any agreement or instrument
to which Subscriber is a party or (iii) any law, statute, rule or regulation to which Subscriber is subject, or any agreement,
order, judgment or decree to which Subscriber is subject.

 

2.10. No Legal Advice
from Company. Subscriber acknowledges it has had the opportunity to review this Agreement and the transactions contemplated by
this Agreement and the other agreements entered into between the parties hereto with Subscriber’s own legal counsel and investment
and tax advisors. Except for any statements or representations of the Company made in this Agreement and the other agreements entered
into between the parties hereto, Subscriber is relying solely on such counsel and advisors and not on any statements or representations
of the Company or any of its representatives or agents for legal, tax or investment advice with respect to this investment, the
transactions contemplated by this Agreement or the securities laws of any jurisdiction.

 

2.11. Reliance on Representations
and Warranties. Subscriber understands the Units are being offered and sold to Subscriber in reliance on exemptions from the registration
requirements under the Securities Act, and analogous provisions in the laws and regulations of various states, and that the Company
is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of Subscriber
set forth in this Agreement in order to determine the applicability of such provisions.

 

2.12. No General Solicitation.
Subscriber is not subscribing for the Units as a result of or subsequent to any general solicitation or general advertising, including
but not limited to any advertisement, article, notice or other communication published in any newspaper, magazine, or similar media
or broadcast over television or radio, or presented at any seminar or meeting or in a registration statement with respect to the
IPO filed with the Securities and Exchange Commission (“SEC”).

 

    3

     

    

 

2.13. Legend. Subscriber
acknowledges and agrees the certificates evidencing each of the Securities shall bear a restrictive legend (the “Legend”),
in form and substance substantially as set forth in Section 4 hereof.

 

3. Representations,
Warranties and Covenants of the Company

 

The Company represents
and warrants to, and agrees with, Subscriber that:

 

3.1. Valid Issuance
of Capital Stock. The total number of shares of all classes of capital stock which the Company has authority to issue is 100,000,000
shares of Class A Common Stock, 10,000,000 shares of Class B Common Stock, $0.0001 par value per share (the “Class B Common
Stock”), and 1,000,000 shares of preferred stock, $0.0001 par value per share (“Preferred Stock”).
As of the date hereof, the Company has issued and outstanding 6,325,00 shares of Class B Common Stock (of which up to 825,000 shares are subject to forfeiture as described in the Registration Statement), no shares of Class A Common Stock and no shares of
Preferred Stock. All of the issued shares of capital stock of the Company have been duly authorized, validly issued, and are fully
paid and non-assessable.

 

3.2 Title to Securities.
Upon issuance in accordance with, and payment pursuant to, the terms hereof and that certain warrant agreement to be entered into
between the Company and Continental, as warrant agent (the “Warrant Agreement”), as the case may be, each of
the Units, Placement Shares, Placement Warrants and Warrant Shares will be duly and validly issued, fully paid and non-assessable.
On the date of issuance of the Units and Warrant Shares shall have been reserved for issuance. Upon issuance in accordance with,
and payment pursuant to, the terms hereof and the Warrant Agreement, as the case may be, Subscriber will have or receive good title
to the Units, Placement Shares and Placement Warrants, free and clear of all liens, claims and encumbrances of any kind, other
than (i) transfer restrictions hereunder and pursuant to the Insider Letter and (ii) transfer restrictions under federal and state
securities laws.

 

3.3. Organization and
Qualification. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State
of Delaware and has the requisite corporate power to own its properties and assets and to carry on its business as now being conducted.

 

3.4. Authorization;
Enforcement. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this
Agreement and to issue the Securities in accordance with the terms hereof, (ii) the execution, delivery and performance of this
Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary
corporate action, and no further consent or authorization of the Company or its Board of Directors or stockholders is required,
and (iii) this Agreement constitutes valid and binding obligations of the Company enforceable against the Company in accordance
with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance, moratorium,
reorganization, or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or
by equitable principles of general application and except as enforcement of rights to indemnity and contribution may be limited
by federal and state securities laws or principles of public policy.

 

3.5. No Conflicts.
The execution, delivery and performance of this Agreement and the consummation by the Company of the transactions contemplated
hereby do not (i) result in a violation of the Company’s certificate of incorporation or by-laws, (ii) conflict with, or
constitute a default under any agreement or instrument to which the Company is a party or (iii) any law statute, rule or regulation
to which the Company is subject or any agreement, order, judgment or decree to which the Company is subject. Other than any SEC
or state securities filings which may be required to be made by the Company subsequent to the Closing, and any registration statement
which may be filed pursuant thereto, the Company is not required under federal, state or local law, rule or regulation to obtain
any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or self-regulatory
entity in order for it to perform any of its obligations under this Agreement or issue the Units, Placement Shares, Placement Warrants
or Warrant Shares in accordance with the terms hereof.

 

    4

     

    

 

4. Legends

 

4.1. Legend. The Company
will issue the Units, Placement Shares and Placement Warrants, and when issued, the Warrant Shares, purchased by the Subscriber
in the name of the Subscriber. The Securities will bear the following Legend and appropriate “stop transfer” instructions:

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR
OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR SUCH LAWS OR AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL FOR THIS CORPORATION, IS AVAILABLE.”

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO LOCKUP PURSUANT TO AN INSIDER LETTER BETWEEN, AMONG OTHERS, HEALTHCARE
MERGER CORP. AND HCMC SPONSOR LLC AND MAY ONLY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED DURING THE TERM OF
THE LOCKUP PURSUANT TO THE TERMS SET FORTH IN THE INSIDER LETTER.”

 

4.2. Subscriber’s
Compliance. Nothing in this Section 4 shall affect in any way Subscriber’s obligations and agreements to comply with all
applicable securities laws upon resale of the Securities.

 

4.3. Company’s
Refusal to Register Transfer of the Securities. The Company shall refuse to register any transfer of the Securities, if in the
sole judgment of the Company such purported transfer would not be made (i) pursuant to an effective registration statement filed
under the Securities Act, or pursuant to an available exemption from the registration requirements of the Securities Act and (ii)
in compliance herewith and with the Insider Letter.

 

4.4 Registration Rights.
The Subscriber will be entitled to certain registration rights which will be governed by a registration rights agreement (“Registration
Rights Agreement”) to be entered into between, among others, the Subscriber and the Company, on or prior to the effective
date of the Registration Statement.

 

5. Waiver
of Liquidation Distributions.

 

In connection with
the Securities purchased pursuant to this Agreement, Subscriber hereby waives any and all right, title, interest or claim of any
kind in or to any distributions of the amounts in the Trust Account with respect to the Securities, whether (i) in connection with
the exercise of redemption rights if the Company consummates the Business Combination, (ii) in connection with any tender offer
conducted by the Company prior to a Business Combination, (iii) upon the Company’s redemption of shares of Common Stock sold
in the Company’s IPO upon the Company’s failure to timely complete the Business Combination or (iv) in connection with
a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation (A) to modify
the substance or timing of the Company’s obligation to redeem 100% of the Company’s public shares if the Company does
not timely complete the Business Combination or (B) with respect to any other provision relating to stockholders’ rights
or pre-Business Combination activity. In the event a Subscriber purchases shares of Common Stock in the IPO or in the aftermarket,
any additional shares so purchased shall be eligible to receive the redemption value of such shares of Common Stock upon the same
terms offered to all other purchasers of Common Stock in the IPO in the event the Company fails to consummate the Business Combination.

 

6. Terms of
Placement Warrants. Each Placement Warrant shall have the terms set forth in the Warrant Agreement.

 

7. [Reserved].

 

    5

     

    

 

8. Terms
of the Units and Placement Warrants

 

8.1 The Units and their
component parts are substantially identical to the units to be offered in the IPO except that: (i) the Units and component parts
will be subject to transfer restrictions described in the Insider Letter, (ii) the Placement Warrants will be non-redeemable so
long as they are held by the initial holder thereof (or any of its permitted transferees), and may be exercisable on a “cashless”
basis if held by a Subscriber or its permitted transferees, as further described in the Warrant Agreement and (iii) the Units and
component parts are being purchased pursuant to an exemption from the registration requirements of the Securities Act and will
become freely tradable only after the expiration of the lockup described above in clause (i) and they are registered pursuant to
the Registration Rights Agreement to be signed on or before the date of the Prospectus or an exemption from registration is available.

 

8.2 Subscriber agrees
to vote the Placement Shares in accordance with the terms of the Insider Letter and as otherwise described in the Registration
Statement.

 

9. Governing
Law; Jurisdiction; Waiver of Jury Trial

 

This Agreement shall
be governed by and construed in accordance with the laws of the State of New York for agreements made and to be wholly performed
within such state. The parties hereto hereby waive any right to a jury trial in connection with any litigation pursuant to this
Agreement and the transactions contemplated hereby.

 

10. Assignment; Entire Agreement;
Amendment

 

10.1. Assignment. Neither
this Agreement nor any rights hereunder may be assigned by any party to any other person other than by a Subscriber to a person
agreeing to be bound by the terms hereof, including the waiver contained in Section 7 hereof.

 

10.2. Entire Agreement.
This Agreement sets forth the entire agreement and understanding between the parties as to the subject matter thereof and merges
and supersedes all prior discussions, agreements and understandings of any and every nature among them.

 

10.3. Amendment. Except
as expressly provided in this Agreement, neither this Agreement nor any term hereof may be amended, waived, discharged or terminated
other than by a written instrument signed by all of the parties hereto.

 

10.4. Binding upon
Successors. This Agreement shall be binding upon and inure to the benefit of the parties hereto and to their respective heirs,
legal representatives, successors and permitted assigns.

 

11. Notices

 

11.1 Notices. Unless
otherwise provided herein, any notice or other communication to a party hereunder shall be sufficiently given if in writing and
personally delivered or sent by facsimile or other electronic transmission with copy sent in another manner herein provided or
sent by courier (which for all purposes of this Agreement shall include Federal Express or other recognized overnight courier)
or mailed to said party by certified mail, return receipt requested, at its address provided for herein or such other address as
either may designate for itself in such notice to the other. Communications shall be deemed to have been received when delivered
personally, on the scheduled arrival date when sent by next day or 2nd-day courier service, or if sent by facsimile upon receipt
of confirmation of transmittal or, if sent by mail, then three days after deposit in the mail. If given by electronic transmission,
such notice shall be deemed to be delivered (a) if by electronic mail, when directed to an electronic mail address at which the
stockholder has consented to receive notice; (b) if by a posting on an electronic network together with separate notice to the
stockholder of such specific posting, upon the later of (1) such posting and (2) the giving of such separate notice; and (c) if
by any other form of electronic transmission, when directed to the stockholder.

 

    6

     

    

 

12. Counterparts

 

This Agreement may
be executed in one or more counterparts, all of which when taken together shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both
parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail
delivery of a “pdf” format data file, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

13. Survival;
Severability

 

13.1. Survival. The
representations, warranties, covenants and agreements of the parties hereto shall survive the Closing Dates.

 

13.2. Severability.
In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable
or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability shall
be effective if it materially changes the economic benefit of this Agreement to any party.

 

14. Headings.

 

The titles and subtitles
used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 

[remainder of page intentionally left blank]

 

    7

     

    

  

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement to be effective as of the date first set forth above.

 

	 	COMPANY:
	 	 
	 	HEALTHCARE MERGER CORP.
	 	 	 
	 	By:	/s/ Dennis M. Conroy
	 	 	Name: Dennis M. Conroy 
	 	 	Title: Chief Financial Officer

 

	 	SUBSCRIBER:
	 	 
	 	HCMC SPONSOR LLC
	 	 	 
	 	By:	/s/ Steven J. Shulman
	 	 	Name: Steven J. Shulman
	 	 	Title: Managing Member

 

[Unit Subscription Agreement with Sponsor]

 

 

8Exhibit

SECOND AMENDMENT TO THE
NAVISTAR, INC.
MANAGERIAL RETIREMENT OBJECTIVE PLAN

WHEREAS, Navistar, Inc. (the “Company”) maintains the Navistar, Inc. Managerial Retirement Objective Plan, as amended and restated effective June 1, 2016 (the “Plan”); and
WHEREAS, the Company has reserved the right to amend the Plan pursuant to Section 7.3 therein;
NOW THEREFORE BE IT RESOLVED, that by virtue and in exercise of the power to amend the Plan reserved to the Company, the Plan be and is hereby amended, effective as of the dates specified herein, as follows:
1.By amending Section 1.19 of the Plan, effective January 1, 2019, to read in its entirety as follows:
“1.19    ‘RPSE’ shall mean the Navistar, Inc. Retirement Plan for Salaried Employees, as may be amended from time to time, and, on and after January 1, 2017, and prior to January 1, 2019, its continuing benefit structure within the Navistar, Inc. Salaried Employees Pension Plan; and, on and after January 1, 2019, its respective continuing benefit structures within the Navistar, Inc. Salaried Employees Pension Plan No. 1 and within the Navistar, Inc. Salaried Employees Pension Plan No. 2, as they may be amended from time to time.”
2.By amending Section 8 of the Plan, effective as of April 1, 2018, by inserting the below language as Section 8.7 and re-numbering the current Section 8.7 (titled “Responsibility For Legal Effect”) as Section 8.8:
		
	“8.7 
	Claims and Appeals Procedure Applicable to Applications for Disability Retirement filed on or after April 1, 2018 

(a)    If and to the extent a claim for benefits under the plan is conditioned upon a determination of disability (excluding any determination made by a party other than the Plan Administrator for purposes other than making a benefit determination under the Plan, such as the provision of Plan benefits to any person who has been determined to be disabled under the Federal Social Security Act or under an employer’s long term disability plan), such claim for benefits shall be processed in accordance with the requirements of ERISA Section 503 applicable to disability claims and the remaining provisions of this Section 8.7. 
(b)    Notification of Denial of Disability Retirement
In addition to the other general provisions of Section 8.6, the following specific provisions of this Section 8.7(b) shall apply to applications for a Disability Retirement Allowance made on or after April 1, 2018 if applicable pursuant to Section 8.7(a). The written notification of the benefit denial of an application for a Disability Retirement Allowance will set forth, in a manner calculated to be understood by the Participant or beneficiary, the following:
(1)    A discussion of the decision, including an explanation of the basis for disagreeing with or not following:
(i)    The views presented by the Participant or beneficiary to the Plan Administrator of health care professionals treating the Participant or beneficiary and vocational professionals who evaluated the Participant or beneficiary; 
(ii)    The views of medical or vocational experts whose advice was obtained on behalf of the Plan Administrator in connection with a Participant or beneficiary’s adverse benefit determination, without regard to whether the advice was relied upon in making the benefit determination; and 
(iii)    A disability determination regarding the Participant or beneficiary made under the Federal Social Security Act and presented by the Participant or beneficiary to the Plan Administrator;
(2)    If the benefit denial is based on a medical necessity or experimental treatment or similar exclusion or limit, either an explanation of the scientific or clinical judgment for the determination, applying the terms of the Plan to the Participant or beneficiary’s medical circumstances, or a statement that such explanation will be provided free of charge upon request;
(3)    Either the specific internal rules, guidelines, protocols, standards or other similar criteria of the Plan relied upon in making the adverse determination or, alternatively, a statement that such rules, guidelines, protocols, standards or other similar criteria of the Plan do not exist; and

1

(4)    A statement that the Participant or beneficiary is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the Participant or beneficiary’s claim for benefits. 
(5)    The notification shall be provided in a culturally and linguistically appropriate manner in accordance with the requirements described in Department of Labor Regulation § 2560.503-1(o).
(c)    Notification of Denial of Disability Retirement Applications on Appeal
In addition to the other general provisions of Section 8.6, the following specific provisions of this Section 8.7(c) shall apply to appeals for Disability Retirement Allowance applications made on or after April 1, 2018 if applicable pursuant to Section 8.7(a). The written notification of the benefit denial of the appeal will set forth, in a manner calculated to be understood by the Participant or beneficiary, the following:
(1)    A discussion of the decision, including an explanation of the basis for disagreeing with or not following:
(i)    The views presented by the Participant or beneficiary to the Plan Administrator of health care professionals treating the Participant or beneficiary and vocational professionals who evaluated the Participant or beneficiary; 
(ii)    The views of medical or vocational experts whose advice was obtained on behalf of the Plan Administrator in connection with a Participant or beneficiary’s adverse benefit determination, without regard to whether the advice was relied upon in making the benefit determination; and 
(iii)    A disability determination regarding the Participant or beneficiary made under the Federal Social Security Act and presented by the Participant or beneficiary to the Plan Administrator;
(2)    If the adverse benefit determination is based on a medical necessity or experimental treatment or similar exclusion or limit, either an explanation of the scientific or clinical judgment for the determination, applying the terms of the Plan to the Participant or beneficiary’s medical circumstances, or a statement that such explanation will be provided free of charge upon request;
(3)    Either the specific internal rules, guidelines, protocols, standards or other similar criteria of the Plan relied upon in making the adverse determination or, alternatively, a statement that such rules, guidelines, protocols, standards or other similar criteria of the Plan do not exist; and
(4)    The notification shall be provided in a culturally and linguistically appropriate manner in accordance with the requirements described in Department of Labor Regulation § 2560.503-1(o).
(d)    Provision of New or Additional Evidence or Rationale to Participant or Beneficiary 
(1)    Before the Plan Administrator can issue an adverse benefit determination on review of a Disability Retirement Allowance claim that is subject to the provisions of this Section 8.7 pursuant to Section 8.7(a), the Plan Administrator shall provide the Participant or beneficiary, free of charge, any new or additional evidence considered, relied upon, or generated by the Plan Administrator, or other person making the benefit determination (or at the direction of the Plan Administrator, or such other person) in connection with the claim. Such evidence will be provided as soon as possible and sufficiently in advance of the date on which the notice of adverse benefit determination on review is required to be provided to give the Participant or beneficiary a reasonable opportunity to respond prior to that date. 
(2)    Before the Plan Administrator can issue an adverse benefit determination on review of a Disability Retirement Allowance claim that is subject to the provisions of this Section 8.7 pursuant to Section 8.7(a), based on a new or additional rationale, the Plan Administrator shall provide the Participant or beneficiary, free of charge, with the rationale. Such rationale must be provided as soon as possible and sufficiently in advance of the date on which the notice of adverse benefit determination on review is required to be provided to give the Participant or beneficiary a reasonable opportunity to respond prior to that date.
(e)    Deemed Exhaustion for Disability Retirement Applications filed on or after April 1, 2018

2

(1)    Generally, if the Plan or Plan Administrator fails to establish or follow claims procedures consistent with the requirements of Sections 8.6 or 8.7 with respect to a Disability Retirement Allowance claim that is subject to the provisions of this Section 8.7 pursuant to Section 8.7(a), a Participant or beneficiary will be deemed to have exhausted the administrative remedies available under the Plan and shall be entitled to pursue any available remedies under ERISA Section 502(a).
(2)    In addition, if the Plan or Plan Administrator fails to strictly adhere to all the requirements of Sections 8.6 or 8.7 with respect to a Disability Retirement Allowance claim that is subject to the provisions of this Section 8.7 pursuant to Section 8.7(a), the Participant or beneficiary is deemed to have exhausted the administrative remedies available under the Plan (unless the violations are “de minimis” in accordance with Department of Labor Regulation § 2560.503-1(l)(2)(ii)). Accordingly, the Participant or beneficiary is entitled to pursue any available remedies under ERISA Section 502(a). If a Participant or beneficiary chooses to pursue remedies under ERISA Section 502, in these circumstances the claim or appeal is deemed denied on review without the exercise of discretion by an appropriate fiduciary.
(f)    With respect to a Disability Retirement Allowance claim that is subject to the provisions of this Section 8.7 pursuant to Section 8.7(a), the Plan Administrator shall ensure, with respect to such claims of disability, that all claims are adjudicated in a manner designed to ensure the independence and impartiality of the persons involved in making the decision. Accordingly, no decisions regarding hiring, compensation, termination, promotion, or other similar matters with respect to any individual involved in the claims and appeals process (such as a claims adjudicator or medical or vocational expert) will be made based upon the likelihood that the individual will support the denial of benefits.”
3.By amending the first sentence of Section 2.4 of Supplement A to the Plan, effective January 1, 2019, to read in its entirety as follows:
“The Retirement Plan for Employees of IC Bus, LLC, as may be amended from time to time; and, on and after December 30, 2016, and prior to January 1, 2019, the Navistar, Inc. Salaried Employees Pension Plan; and, on and after January 1, 2019, the Navistar, Inc. Salaried Employees Pension Plan No. 2 (each to the extent they are applicable to participants spun off from the Retirement Plan for Employees of IC Bus, LLC), as they may be amended from time to time, shall specifically be included among the plans and programs described in Section 4.1(c)(4) of the Plan.”
4.By amending the first part of the first sentence of Section 3.4 of Supplement A to the Plan, up to and including the parenthetical “(the “Conway Pension Plan”)”, effective January 1, 2019, to read in its entirety as follows:
“The Retirement Plan for Employees of IC Bus, LLC, as may be amended from time to time; and, on and after December 30, 2016, and prior to January 1, 2019, the Navistar, Inc. Salaried Employees Pension Plan; and, on and after January 1, 2019, the Navistar, Inc. Salaried Employees Pension Plan No. 2 (each to the extent they are applicable to participants spun off from the Retirement Plan for Employees of IC Bus, LLC), as they may be amended from time to time (the “Conway Pension Plan”)”
*  *  *  *  *  *  *

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]